Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Turk Ilac ve SerumnayiIST:TRILC -0.85%61 Debt-to-Equity is 1.44 as of Sep. 2025, which is 95% above its 10-year median of 0.74. GuruFocus rates IST:TRILC with a GF Score™ of 61/100 and a GF Value™ of ₺3.68 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 812 Drug Manufacturers companies, Turk Ilac ve Serumnayi ranks worse than 91.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Turk Ilac ve Serumnayi's Debt-to-Equity or its related term are showing as below:
IST:TRILC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.29 Med: 0.74 Max: 1.44
Current: 1.44
During the past 5 years, the highest Debt-to-Equity Ratio of Turk Ilac ve Serumnayi was 1.44. The lowest was 0.29. And the median was 0.74.
IST:TRILC's Debt-to-Equity is ranked worse than 91.87% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs IST:TRILC: 1.44
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Turk Ilac ve Serumnayi Debt-to-Equity Related Terms
Turk Ilac ve Serumnayi Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Turk Ilac ve Serumnayi's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IST:TRILC vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turk Ilac ve Serumnayi Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Turk Ilac ve Serumnayi's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turk Ilac ve Serumnayi (IST:TRILC) has a Debt-to-Equity of 1.44 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Turk Ilac ve Serumnayi and its competitors. This is 95% above median its historical median of 0.74. Over the past decade, Turk Ilac ve Serumnayi's Debt-to-Equity has ranged from 0.29 to 1.44. According to the industry distribution chart, Turk Ilac ve Serumnayi ranks #746 out of 812 companies in the Drug Manufacturers industry, placing it in the top 91.9%.
Is Turk Ilac ve Serumnayi's Debt-to-Equity too high?
Turk Ilac ve Serumnayi's current Debt-to-Equity of 1.44 is 95% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 1.44. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Turk Ilac ve Serumnayi's value of 1.44 is 433.3% above this industry median. Based on the distribution chart, Turk Ilac ve Serumnayi ranks #746 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Turk Ilac ve Serumnayi has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Turk Ilac ve Serumnayi's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Turk Ilac ve Serumnayi ranks #746 out of 812 companies for Debt-to-Equity. This places Turk Ilac ve Serumnayi in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Turk Ilac ve Serumnayi's value of 1.44 is 433.3% above this benchmark. Historically, Turk Ilac ve Serumnayi's own Debt-to-Equity has ranged from 0.29 to 1.44 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 0.27, Turk Ilac ve Serumnayi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turk Ilac ve Serumnayi's current Debt-to-Equity of 1.44 is 433.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Turk Ilac ve Serumnayi and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turk Ilac ve Serumnayi's current Debt-to-Equity is 1.44, which is 95% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turk Ilac ve Serumnayi stock overvalued right now?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi (IST:TRILC) is currently considered Possible Value Trap. The stock's GF Value™ is ₺3.68, compared to a current price of ₺1.17 — trading 68.2% below its estimated fair value. The current Debt-to-Equity is 1.44, which is 95% above median its 10-year median of 0.74 and 433.3% above the Drug Manufacturers industry median of 0.27. Turk Ilac ve Serumnayi's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Turk Ilac ve Serumnayi (IST:TRILC), the current Debt-to-Equity is 1.44 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Turk Ilac ve Serumnayi (IST:TRILC) Overvalued in 2026?
Based on GuruFocus' analysis, Turk Ilac ve Serumnayi stock appears to be undervalued.
The current stock price of ₺1.17 is trading 68.2% below its estimated GF Value™ of ₺3.68.
GuruFocus considers Turk Ilac ve Serumnayi to be Possible Value Trap.
Key valuation signals for IST:TRILC:
Debt-to-Equity: 1.44 (95% above median its 10-year median of 0.74)
GF Value™: ₺3.68 vs. price of ₺1.17 (68.2% below fair value)
Industry Position: 433.3% above the Drug Manufacturers median (#746 of 812)
No single metric tells the full story. See the IST:TRILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:TRILC has been successfully added to your 
